OCGN Ocugen, Inc.
Ocugen, Inc. (OCGN) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.06 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +8.0% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe.
Sector
Healthcare
Industry
Biotechnology